A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammation
O’Shaughnessy, Joyce, DeMichele, Angela, Ma, Cynthia X., Richards, Paul, Yardley, Denise A., Wright, Gail Shaw, Kalinsky, Kevin, Steis, Ronald, Diab, Sami, Kennealey, Gerard, Geschwindt, Ryan, Jiang,Language:
english
Journal:
Breast Cancer Research and Treatment
DOI:
10.1007/s10549-018-4770-6
Date:
April, 2018
File:
PDF, 786 KB
english, 2018
File converter
More search results
More benefits 
